
Celltrion and Onconic team up on ovarian cancer combo with dual-target PARP drug
Korean biotech Onconic Therapeutics is teaming up with biosimilar giant Celltrion to develop a new treatment option for relapsed ovarian cancer, combining Onconic’s dual-mechanism small molecule nesuparib with Vegzelma, Celltrion’s bevacizumab biosimilar …